Sana Biotechnology: Engineering Cell Therapies Across Oncology, Genetic Disorders, and Autoimmune Disease
核心洞察
Sana Biotechnology is advancing a dual-platform cell engineering strategy encompassing both ex vivo and in vivo approaches to create medicines for diseases with significant unmet need.
The company's oncology pipeline targets CD19 (搜索)+ cancers including non-Hodgkin lymphoma (搜索), CLL, and ALL, as well as multiple myeloma (搜索), with programs such as SG295, SC291, and SG221.
Beyond oncology, Sana is developing candidates for genetic disorders (SG328 for OTC deficiency), blood disorders (SG418 for sickle cell disease (搜索)), type 1 diabetes (SC451), and CNS disorders including Huntington's disease (搜索) (SC379).
Sana Biotechnology, Inc. (SANA) is pursuing an ambitious vision: turning the engineering of cells into medicines that address a broad spectrum of diseases. Founded with a dual-platform strategy, the company is developing both ex vivo (cells engineered outside the body) and in vivo (cells engineered inside the body) technologies to tackle what its leadership describes as the most important challenges in cell-based therapeutics.
Steve Harr, MD, President and CEO, articulated the company's founding vision at the Goldman Sachs 47th Annual Global Healthcare Conference: "The company when we started it, we had a vision. And that vision was to try to go after and tackle what we thought were the most important challenges in making our vision a reality, which was turning this idea of engineering cells or modifying cells into medicines." He added, "If you take a step back and think about almost every disease you can think of is caused by either a missing and damaged cell or a cell that's kind of gone awry."
Oncology Pipeline Targets Hematologic Malignancies
Sana's most advanced product candidates are focused on oncology. The company is developing multiple programs directed at CD19 (搜索)+ cancers, including SG295, SG242, and SC291. These candidates are designed to treat non-Hodgkin lymphoma (搜索), chronic lymphocytic leukemia (搜索) (CLL), and acute lymphoblastic leukemia (搜索) (ALL). For multiple myeloma (搜索), Sana is advancing SG221, SG239, and SC255, aiming to provide novel therapeutic options for patients with this challenging plasma cell malignancy.
Expanding Beyond Cancer
The company's pipeline extends well beyond oncology. SG328 is being developed for ornithine transcarbamylase (OTC) deficiency, a genetic disorder affecting the urea cycle. In blood disorders, SG418 targets sickle cell disease (搜索) and beta-thalassemia (搜索). Sana is also pursuing SC451 for type 1 diabetes mellitus (搜索), and SC379 for central nervous system disorders, including secondary progressive multiple sclerosis (搜索), Pelizaeus-Merzbacher disease (搜索), and Huntington's disease (搜索).
Leadership and Development Stage
Sana Biotechnology was co-founded by Steve Harr, who previously served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics until its acquisition by Celgene in early 2018. He also served on the Board of Directors of Loxo Oncology prior to its acquisition by Eli Lilly in 2019.
The executive team includes Brian Piper, appointed Executive Vice President and CFO in February 2026, who brings over 25 years of financial and operational experience from roles at Scorpion Therapeutics, Prelude Therapeutics, and Shire Pharmaceuticals. Dhavalkumar Patel, MD, PhD, joined as Executive Vice President and Chief Scientific Officer in 2024, following his tenure as CSO at UCB, where his work contributed to the registration of bimekizumab (Bimzelx) and rozanolixizumab (Rystiggo). Aaron Grossman serves as Executive Vice President and Chief Legal Officer as of October 2025, and John Gerecitano, MD, PhD, leads Oncology Research and Development.
It is important to note that Sana Biotechnology does not currently have any approved or commercialized products. All programs remain in the research and development phase, and the company has no major commercial customers. The therapies described represent product candidates in the development pipeline, and their safety and efficacy have not yet been established through regulatory review.